Dr. Braunstein on Considerations for Stem Cell Transplant Eligibility in Myeloma

Video

In Partnership With:

Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

Marc J. Braunstein, MD, PhD, clinical assistant professor in the Department of Medicine and co-director of the Autologous Stem Cell Transplant Program at NYU Winthrop Hospital of NYU Langone Health’s Perlmutter Cancer Center, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

It is important to be able to assess a patient not just when first meeting them and making a diagnosis of multiple myeloma, but at every step of their induction therapy to determine how fit they are for stem cell transplant, says Braunstein.

Ultimately, the time at which a patient is assessed for fitness of transplant is when they are first diagnosed and then right before stem cell transplant. Typically, the patient will be referred to a bone marrow transplant specialist, says Braunstein.

Some of the factors to consider when determining a patient’s eligibility for the procedure include: performance status, functional status, response to treatment, whether they achieved a partial remission or a very good partial remission, vital organ function, whether the patient understands the risks and benefits of the procedure, and whether they have a support system to allow them to go through the process, concludes Braunstein.

Related Videos
Amma Asare, MD, PhD
Sundar Jagannath, MBBS
Elias Jabbour, MD
Rebecca Klisovic, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Jubilee Brown, MD
Changchun Deng, MD, PhD
Laura J. Chambers, DO
Casey M. Cosgrove, MD